Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;11(11):975-8.
doi: 10.1038/ni1110-975.

A model for harmonizing flow cytometry in clinical trials

Holden T Maecker  1 , J Philip McCoy Jr; FOCIS Human Immunophenotyping Consortium; Michael Amos, John Elliott, Adolfas Gaigalas, Lili Wang, Richard Aranda, Jacques Banchereau, Chris Boshoff, Jonathan Braun, Yael Korin, Elaine Reed, Judy Cho, David Hafler, Mark Davis, C Garrison Fathman, William Robinson, Thomas Denny, Kent Weinhold, Bela Desai, Betty Diamond, Peter Gregersen, Paola Di Meglio, Frank O Nestle, Mark Peakman, Federica Villanova, John Ferbas, Elizabeth Field, Aaron Kantor, Thomas Kawabata, Wendy Komocsar, Michael Lotze, Jerry Nepom, Hans Ochs, Raegan O'Lone, Deborah Phippard, Scott Plevy, Stephen Rich, Mario Roederer, Dan Rotrosen, Jung-Hua Yeh
Affiliations

A model for harmonizing flow cytometry in clinical trials

Holden T Maecker et al. Nat Immunol. 2010 Nov.

Erratum in

  • Nat Immunol. 2010 Nov;11(11):979. DiMeglio, Paola [corrected to Di Meglio, Paola]; Nestle, Frank [corrected to Nestle, Frank O]; Villnova, Federica [corrected to Villanova, Federica]
  • Nat Immunol. 2011 Mar;12(3):271

Abstract

Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at http://www.nature.com/natureimmunology/.

Figures

Figure 1
Figure 1
Flow chart of decisions that can affect the quality of data produced in clinical trials in which immunological parameters are monitored by flow cytometry.
Figure 2
Figure 2
Proposed mixed model of the operation of a multisite clinical trial.
See this image and copyright information in PMC

References

    1. Maecker HT, et al. BMC Immunol. 2005;6:13. - PubMed
    1. Perfetto SP, Chattopadhyay PK, Roederer M. Nat Rev Immunol. 2004;4:648–655. - PubMed
    1. Maecker HT. Methods Mol Biol. 2009;485:375–391. - PMC - PubMed
    1. Suni MA, et al. BMC Immunol. 2003;4:9. - PMC - PubMed
    1. Davis MM. Immunity. 2008;29:835–838. - PMC - PubMed

LinkOut - more resources